TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

Key Points

• Canaccord Genuity cut its price target on TransMedics from $152 to $124 but kept a "buy" rating, implying roughly a 70% upside from the stock's recent price.
• TransMedics reported a sharp Q1 EPS miss of $0.30 versus $0.62 expected and slightly below‑consensus revenue ($173.93M vs. $174.48M), driving a large intraday drop to $72.92 on heavy volume and prompting margin concerns.
• Analyst views are mixed—multiple firms trimmed targets and at least one downgraded the stock while overall ratings split six Buy / six Hold with an average target of $135—and insiders have sold shares recently amid heavy institutional ownership.

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price dropped by equities researchers at Canaccord Genuity Group from $152.00 to $124.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's price objective points to a potential upside of 70.05% from the company's current price.

Other research analysts also recently issued research reports about the company. Stifel Nicolaus cut their target price on TransMedics Group from $130.00 to $85.00 and set a "hold" rating for the company in a research note on Wednesday. Wall Street Zen cut TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, February 28th. TD Cowen lowered their price target on TransMedics Group from $190.00 to $120.00 and set a "buy" rating on the stock in a report on Wednesday. JPMorgan Chase & Co. raised their price target on TransMedics Group from $114.00 to $149.00 and gave the company a "neutral" rating in a report on Wednesday, February 25th. Finally, Piper Sandler lowered their price target on TransMedics Group from $160.00 to $120.00 and set an "overweight" rating on the stock in a report on Wednesday. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $135.00.

TransMedics Group Stock Performance

TMDX traded down $22.01 during trading hours on Wednesday, hitting $72.92. The stock had a trading volume of 7,727,054 shares, compared to its average volume of 979,563. TransMedics Group has a 1 year low of $70.00 and a 1 year high of $156.00. The company's fifty day simple moving average is $116.57 and its 200 day simple moving average is $125.96. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The stock has a market cap of $2.52 billion, a PE ratio of 14.88 and a beta of 2.07.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.48 million. During the same quarter in the prior year, the business earned $0.70 EPS. The firm's revenue for the quarter was up 21.2% compared to the same quarter last year. Equities analysts anticipate that TransMedics Group will post 2.48 earnings per share for the current year.

Insider Activity

In other news, insider Nicholas Corcoran sold 2,966 shares of TransMedics Group stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the sale, the insider directly owned 29,831 shares in the company, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the completion of the sale, the insider owned 13,091 shares in the company, valued at approximately $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently added to or reduced their stakes in TMDX. Royal Bank of Canada boosted its holdings in TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock worth $1,314,000 after acquiring an additional 868 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company's stock worth $1,059,000 after purchasing an additional 938 shares during the last quarter. Finally, M&T Bank Corp purchased a new position in shares of TransMedics Group in the second quarter worth $209,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group News Roundup

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Quarterly revenue growth and continued product demand — TMDX posted Q1 revenue up ~21% year‑over‑year driven by strong demand for its Organ Care System (OCS), showing continued top‑line momentum. PR Newswire: Q1 Results
• Positive Sentiment: Some analysts remain bullish despite cuts — Several firms trimmed price targets but retained buy/overweight stances (e.g., TD Cowen, Piper Sandler, Needham), signaling that some investors still see multi‑quarter upside from long‑term adoption. Benzinga: Analyst Notes
• Neutral Sentiment: Guidance updated — Management issued FY‑2026 revenue guidance in a range that brackets Wall Street consensus (roughly $727M–$757M vs. $739M consensus), leaving some ambiguity about margin and EPS sensitivity to execution. Slide Deck / Press Release
• Neutral Sentiment: Earnings call transcript available — Management commentary on adoption, logistics growth and margin drivers is available for investors to review for signs of durable improvement. Seeking Alpha: Call Transcript
• Negative Sentiment: Significant EPS miss and margin pressure — TMDX reported $0.30 EPS vs. ~$0.62 consensus and noted falling margins, which is the primary near‑term catalyst for the share decline. Zacks: Q1 Miss & Margins
• Negative Sentiment: Analyst downgrades and price‑target cuts — Multiple firms cut targets and at least one downgraded TMDX to market‑perform, amplifying selling pressure despite some retained buy ratings. Finviz: Analyst Actions
• Negative Sentiment: Market reaction: heavy volume and reset valuation — The combination of the EPS miss, margin concerns and analyst re‑rating produced elevated trading and a rapid re‑pricing versus recent moving averages. Zacks: Earnings & Revenue Miss

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.